19 / 30
Orthopedics and Osteoporosis 2018
N o v e m b e r 2 9 - 3 0 , 2 0 1 8
Am s t e r d a m , N e t h e r l a n d s
Page 39
Journal of Clinical & Experimental Orthopaedics
ISSN: 2471-8416
E u r o p e a n C o n f e r e n c e o n
Orthopedics and
Osteoporosis
L
ifeAid Combo is a composition of vitamins and CBD developed for a wide array of autoimmune conditions, covering Guillain-
Barré, Multiple Sclerosis, Rheumatoid Arthritis, Crohn, Asthma, Vasculitis and Fibromyalgia. LifeAid Combo is a patient
based initiative, created by a patient and tested by the patients via testimonials in the Initial Trial, advised by the expertise of
Baruch Styr, Pharmacist, Batya Kornboim, MD, and Igal Yusim Research. All trial participants have consulted with their personal
physicians, were informed of the risks and volunteered. After a thorough screening process 320 volunteers qualified for the trial
in the Fibromyalgia group, and 255 volunteers qualified for the trial in the Guillain-Barré + MS group. 311 participants finished
the trial in the Fibromyalgia group, 248 participants finished the trial in the Guillain-Barré + MS group. No deaths or medical
emergencies were found on follow up, all dropouts didn’t keep up with the regimen for personal reasons. The participants were
given a self-report questionnaire to fill out once a day regarding the effects of the LifeAid Combo for 100 days over five Life
Aspects: Appetite, Fatigue, Movement, Pain, Sleep. Effectiveness of the treatment was assess through Simple Line Regression,
over 20% is considered to be effective, under 20% was considered to be not-effective.
Results
Guillain-Barré + MS group
Effective
Appetite
68%
Fatigue
41%
Movement
65%
Pain
57%
Sleep
55%
Avissar Koren A
1
and Styr B
2
1
Acc Triza Granot Ltd, Israel
2
The Hebrew University of Jerusalem, Israel
Avissar Koren A et al., J Clin Exp Orthop 2018, Volume: 4
DOI: 10.4172/2471-8416-C1-005
LifeAid Combo Trial – Fibromyalgia, Multiple Sclerosis & Guillain-Barré
Inflammation flaring up during the trial: 0 episodes
Effective
Appetite
68%
Fatigue
37%
Movement
84%
Pain
57%
Sleep
55%
Results Explained
Initial trial results have shown the treatment to have the greatest effect on Appetite, Movement and Pain for the Guillain-Barré
+ MS group. The overall reduction in inflammation flaring up (0 episodes amongst the Guillain-Barré + MS group during the
Fibromyalgia group